Literature DB >> 6385634

A long-term follow-up of patients with essential hypertension treated with captopril.

P Ohman, M Aurell, J Asplund, T Conradsson, K Delin, T Forslund, F Fyhrquist, G Frithz, H Herlitz, B Karlberg.   

Abstract

Seventy-four patients from four short-term studies of captopril in mild-moderate essential hypertension continued in a cooperative long-term efficacy and tolerance program. The duration of observation is 2- greater than 4 years, the total treatment time being 2434 months. No development of resistance to therapy was observed. The total daily dose of captopril has been gradually decreased and in 20 patients changed from t.i.d. to b.i.d. regime. The drug has been well tolerated and only few and mild side-effects have been observed after the initial titration period. The drop-outs (n = 19) were mostly due to non-medical causes (n = 14). Except for one case of proteinuria, no laboratory abnormalities were detected and there were no signs of long-term toxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385634     DOI: 10.1111/j.0954-6820.1984.tb03770.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  4 in total

1.  Cost of antihypertensive treatment: a point of view from India.

Authors:  H K Bali; I S Anand
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

Review 3.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

4.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.